NasdaqGS:EXELBiotechs
FDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test
FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer.
The application is based on pivotal trial data for patients with advanced disease.
This step moves the investigational combination closer to potential commercial use in the United States.
For investors watching NasdaqGS:EXEL, this FDA filing milestone is an important datapoint in the company’s oncology pipeline. Exelixis focuses on cancer therapies, and colorectal cancer is a...